Considering the large number of high quality peer-reviewed publications now avilable, this page is no longer updated in 2021.

We publish this page in the hope that our members, and the antiviral community at large, will find it useful in their quest for a world in which viral outbreaks are no longer a constant major threat.

ISAR members are invited to submit any links that may be of interest for their evaluation and potential addition to this page.

Older information can be found in this page

Links of general interest about the SARS CoV-2 and the COVID-19 outbreak:

GILEAD SCIENCES STATEMENT ON THE SOLIDARITY TRIAL

Remdesivir Clinical Trials

FDA rescinded the emergency authorization for the use of hydroxychloroquine against SARS CoV-2

WHO suspends chloroquine and hydroxychloroquine clinical trials for COVID-19

COVID R&D: Pharmas align behind crowdsourcing solution- A partnership among pharmaceutical companies to speed up progress towards COVID-19 solutions

NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options: Health agencies and leading pharmaceutical companies to join forces to accelerate pandemic response.

A comprehensive statistical description of the pandemic in different countries

A resource developed by economists providing an excellent range of statistical descriptions of the pandemic, with clear explanations of the meaning of the numbers, including their intrinsic  limitations and what do they actually present.

A comprehensive SARS CoV-2/COVID-19 resource center from Biocentury

A collection of information about pre-clinical and clinical trial stage therapeutics, drugs being used in patients, and the current regulation meetings status landscape. In response to the urgency of the COVID-19 crisis, Biocentury is making this information available for free. To visit the portal, please follow this link

The SARS CoV-2/COVID-19 interactive map- a collaborative effort

A collaborative resource to develop a host-pathogens mechanism based disease map  for the pathogenesis of COVID-19. To participate, or to browse through the standardized information as it is being deposited, please follow this link

There is an inverse correlation between COVID-19 and  GDP per capita

Confirmed Deaths versus testing per country

Remdesivir (All Populations Monograph)

SARS-CoV-2 in animals, including pets- Statement from the American Veterinary Medical Association (AVMA)

WHO: Home page for all information and documents regarding the 2019-nCOV 

Epidemiology:

There is an unexpected direct correlation between COVID19 mortality and GDP losses in 2020

Number and frequency of cases, deaths, and tests in different countries

Korea CDC (KCDC) report on number of cases

Italy: Ministero della Salute official reports (in Italian)

Italy: SARS-2 COVID cases by region

China CDC epidemic tracking (updated daily)

Real time tracking of the epidemic by the Center for Systems Science and Engineering (CSSE), John Hopkins University 

Number of confirmed and suspected cases, recoveries, and fatalities ( in Chinese)

WHO epidemic tracking in real time

CDC report on USA cases

Statistical descriptions of COVID-19 global outbreak

Current news:

The protocols for the clinical trials of the SASR CoV-2 vaccines by Astra-Zeneca, Moderna and Pfizer have been published

Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidat

Pfizer announced the initiation of its Phase 1b clinical trial to evaluate the safety of a novel investigational therapeutic for COVID-19, PF-07304814

Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting

Gilead Sciences Statement on the Initiation of Clinical Testing of an Inhaled Solution of Remdesivir for Potential Outpatient Treatment of COVID-19

Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801

At the Epicenter of the Covid-19 Pandemic and Humanitarian Crises in Italy: Changing Perspectives on Preparation and Mitigation- NEJM Catalyst, a view from Italy about the potential major role of nosocomial transmission in the Italian outbreak

A fiasco in the making? As the coronavirus pandemic takes hold, we are making decisions without reliable data - A different opinion

We know enough now to act decisively against Covid-19. Social distancing is a good place to start- A reply to the different opinion

Aggregated scientific information sites:

Novel Coronavirus Information Center from Elsevier

The Lancet 2019-nCoV Resource Centre

New England Journal of Medicine 2019-nCoV publications

Journal of the American Medical Association (JAMA) 2019-CoV updates, news and publications

Imperial College- MRC Center for Global Infectious Disease Analyses information about COVID and SARS CoV-2

COVID-19 Open Research Dataset Challenge (CORD-19) A database of publications in SARS CoV-2/COVID-19 assembled by AI

Pre-prints and Published papers:

HIGHLIGHTED

Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results

Remdesivir for the Treatment of Covid-19 — Final Report

SARS-CoV-2 vaccines in development

Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial

Pathogenesis of COVID-19 from the Perspective of the Damage-Response Framework

SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2

Antiviral treatment of SARS-CoV-2-infected hamsters reveals a weak effect of favipiravir and a complete lack of effect for hydroxychloroquine

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls 

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

RETRACTED - Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis- - Except for Surgisphere CEO Sapan Desal, all other authors have retracted this publication because Surgisphere would not release the original dataset for an independent audit requested by the other co-authors.

Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Remdesivir for the Treatment of Covid-19 — Preliminary Report

Convalescent plasma treatment of severe COVID-19: A matched control study

Respiratory virus shedding in exhaled breath and efficacy of face masks 

A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Reinfection could not occur in SARS-CoV-2 infected rhesus macaques

Evaluation of heating and chemical protocols for inactivating SARS-CoV-2

Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospital -The original preprint was posted a month ago and is under "clinical"

Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19 - No benefits were observed and mortality was higher in the treated groups

Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 

Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period

Spread of SARS-CoV-2 in the Icelandic Population

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)- A Review A thorough review published in JAMA discussing the limited clinical evidence showing beneficial effects for most approaches being used

Compassionate Use of Remdesivir for Patients with Severe Covid-19- A small cohort analysis of compassionate use of remdesivir in which most patients improved, including 57% of patients under mechanical ventilation who were extubated. Mortality for patients under mechanical ventilation was only 13%, and only 1 patient not under mechanical ventilation succumbed to disease.

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

Viral dynamics in mild and severe cases of COVID-19

Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins

ANTIVIRAL THERAPY and PROPHYLAXIS

Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies 

Treatment of 6 COVID-19 Patients with Convalescent Plasma

Treatment of COVID-19 Patients with Convalescent Plasma in Houston, Texas 

The feasibility of convalescent plasma therapy in severe COVID- 19 patients: a pilot study 

Effect of various treatment modalities on the novel coronavirus (nCOV-2019) infection in humans: a systematic review & meta-analysis

Impact of glucocorticoid treatment in SARS-CoV-2 infection mortality: a retrospective controlled cohort study 

Discovery of potent inhibitors of PLproCoV2 by screening a library of selenium-containing compounds 

Human IgG cell neutralizing monoclonal antibodies block SARS-CoV-2 infection

Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease 

Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients 

Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection

Lack of Antiviral Activity of Darunavir against SARS-CoV-2 

Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial 

SARS-CoV-2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles 

Of chloroquine and COVID-19 - A commentary in Antiviral Research highlighting the common failures in attempting to translate the in vitro antiviral activity of chloroquine against a number of viruses into robust in vivo antiviral activity in animal models or humans.

No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial 

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial 

Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRpand nsp14 Exonuclease active-sites

Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2 

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro

Two studies focusing on interactomes to identify potential drugs for repurposing (with the caveat that the safety in COVID-19 patients of drugs with known pharmacological activities is unknown):

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 

A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug- Repurposing 

Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open- label non-randomized clinical trial

Monoclonal antibodies for the S2 subunit of spike of SARS-CoV cross-react with the newly-emerged SARS-CoV-2 

A human monoclonal antibody blocking SARS-CoV-2 infection 

Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion 

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Structure of Mpro from COVID-19 virus and discovery of its inhibitors 

Substrate specificity profiling of SARS-CoV-2 Mpro protease provides basis for anti-COVID-19 drug design 

Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites 

SARS-CoV-2 sensitive to type I interferon pretreatment

Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2

Outcome reporting from protocols of clinical trials of Coronavirus Disease 2019 (COVID-19): a review

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19

Efficient inactivation of SARS-CoV-2 by WHO-recommended hand rub formulations and alcohols 

Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

MOLECULAR VIROLOGY, GENOMICS and EVOLUTION

The coding capacity of SARS-CoV-2

Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic

Binding of the SARS-CoV-2 Spike Protein to Glycans 

Structure of RNA-dependent RNA polymerase from 2019-nCoV, a major antiviral drug target

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Glycosaminoglycan binding motif at S1/S2 proteolytic cleavage site on spike glycoprotein may facilitate novel coronavirus (SARS-CoV-2) host cell entry 

SARS-CoV-2 spike protein binds heparan sulfate in a length- and sequence-dependent manner 

An infectious cDNA clone of SARS-CoV-2 

Gene expression and in situ protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue

The aging transcriptome and cellular landscape of the human lung in relation to SARS-CoV-2

SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems

Bat Coronaviruses in China- A pre-pandemic review discussing why it was important to study bat coronaviruses in China

Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection- an in silicons analysis predicting that dogs would be susceptible

Absence of SARS-CoV-2 infection in cats and dogs in close contact with a cluster of COVID-19 patients in a veterinary campus

Susceptibility of ferrets, cats, dogs, and different domestic animals to SARS-coronavirus-2- an experimental study showing that dogs are fairly resistant to infection

SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation

Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins

SARS-CoV-2 receptor ACE2 and TMPRSS2 are predominantly expressed in a transient secretory cell type in subsegmental bronchial branches

Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensor 

LY6E impairs coronavirus fusion and confers immune control of viral disease 

The architecture of SARS-CoV-2 transcriptome 

Characterization of the SARS-CoV-2 Spike in an Early Prefusion Conformation

Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2

Cryo-electron microscopy structure of the SARS-CoV spike glycoprotein provides insights into an evolution of unique coronavirus spike proteins 

Direct RNA sequencing and early evolution of SARS-CoV-2 

Genome-wide data inferring the evolution and population demography of the novel pneumonia coronavirus (SARS-CoV-2)

Genomic diversity of SARS-CoV-2 in Coronavirus Disease 2019 patients

Discovery of a 382-nt deletion during the early evolution of SARS-CoV-2 

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2

Partial RdRp sequences offer a robust method for Coronavirus subgenus classification

A novel bat coronavirus reveals natural insertions at the S1/S2 cleavage site of the Spike protein and a possible recombinant origin of HCoV-19

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 -_The published paper

Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2

On the origin and continuing evolution of SARS-CoV-2

Response to “On the origin and continuing evolution of SARS-CoV-2”

Evidence for RNA editing in the transcriptome of 2019 Novel Coronavirus 

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Betacoronavirus Adaptation to Humans Involved Progressive Loss of Hemagglutinin-Esterase Lectin Activity -A paper from 2017 describing one potential adaptation that allowed previous betacoronaviruses to cross species barriers and infect humans

Structural basis for the recognition of the 2019-nCoV by human ACE2

Cryo-EM structures of HKU2 and SADS-CoV spike glycoproteins and insights into coronavirus evolution- Structural analyses of the potential evolution of another coronavirus from bats to piglets

Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses -(The actual structure of the receptor binding domain has now been solved)

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

The insert sequence in SARS-CoV-2 enhances spike protein cleavage by TMPRSS

PATHOGENESIS

SARS-CoV-2 lethality decreased over time in two Italian Provinces 

Rhesus macaques can be effectively infected with SARS-CoV-2 via ocular conjunctival route

SARS-CoV2 infection in farmed mink, Netherlands, April 2020 

Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals 

Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility 

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study 

Multiscale 3-dimensional pathology findings of COVID-19 diseased lung using high-resolution cleared tissue microscopy 

Tocilizumab treatment in severe COVID-19 patients attenuates the inflammatory storm incited by monocyte centric immune interactions revealed by single-cell analysis

COVID-19-related mortality by age groups in Europe: A meta-analysis

Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications 

Comparative pathogenesis of COVID-19, MERS and SARS in a non-human primate model 

Recapitulation of SARS-CoV-2 Infection and Cholangiocyte Damage with Human Liver Organoids 

Asymptomatic SARS-CoV-2 infected patients with persistent negative CT findings

DIAGNOSTICS

SARS-CoV-2 specific antibody responses in COVID-19 patient

Covert COVID-19 and false-positive dengue serology in Singapore

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients 

Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report 

Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing

Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient 

Positive RT-PCR Test Results in Patients Recovered From COVID-19

A simple laboratory parameter (eosinopenia) facilitates early identification of COVID-19 patients

CLINICAL

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy

Outbreak of COVID-19 in Germany Resulting from a Single Travel-Associated Primary Case

Covid-19 in Critically Ill Patients in the Seattle Region — Case Series

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019

CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity

Detection of Covid-19 in Children in Early January 2020 in Wuhan, China 

First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA 

Dysregulation of immune response in patients with COVID-19 in Wuhan, China 

Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1

The demand for inpatient and ICU beds for COVID-19 in the US: lessons from Chinese cities 

Influence factors of death risk among COVID-19 patients in Wuhan, China: a hospital-based case-cohort study

First 12 patients with coronavirus disease 2019 (COVID-19) in the United States

Retrospective Analysis of Clinical Features in 101 Death Cases with COVID-19 

Epidemiological and clinical characteristics of COVID-19 in adolescents and young adults 

Virological assessment of hospitalized cases of coronavirus disease 2019 

Aerodynamic Characteristics and RNA Concentration of SARS-CoV-2 Aerosol in Wuhan Hospitals during COVID-19 Outbreak- A small field study

Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Comparison of severe and non-severe COVID-19 pneumonia: review and meta-analysis

Coronavirus in pregnancy and delivery: rapid review and expert consensus 

Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient- A small (n=3) study published in JAMA

Pulmonary Pathology of Early Phase SARS-COV-2 Pneumonia

Clinical characteristics of 101 non-surviving hospitalized patients with COVID-19—A single center, retrospective study 

Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China

Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics

Clinical Characteristics of Coronavirus Disease 2019 in China

Interim Epidemiological and clinical characteristic of COVID-19 28 cases in South Korea - February 27

Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists

The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing

Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

Clinical course and outcomes of critically ill patients with  SARS-CoV-2 pneumonia in Wuhan, China: a single-centered,  retrospective, observational study

Clinical and immunologic features in severe and moderate forms of Coronavirus Disease 2019- Lymphopenia appears common

Clinical characteristics of 50404 patients with 2019-nCoV infection -A meta-analysis

Comparative study of the lymphocyte change between COVID-19 and non-COVID-19 pneumonia cases suggesting uncontrolled inflammation might not be the main reason of tissue injury Lymphopenia appears common

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series

Asymptomatic cases in a family cluster with SARS-CoV-2 infection

Vital Surveillances: The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020

Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China-The largest description of the outbreak (>44,000 cases)

Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents

Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020

Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province

EPIDEMIOLOGY

Jumping back and forth: anthropozoonotic and zoonotic transmission of SARS-CoV-2 on mink farms

Effect of non-pharmaceutical interventions to contain COVID-19 in China

Using influenza surveillance networks to estimate state-specific case detection rates and forecast SARS-CoV-2 spread in the United States

Introductions and early spread of SARS-CoV-2 in the New York City area 

COVID-19 Antibody Seroprevalence in Santa Clara County, California - Analysis using commercial serological tests with yet not fully characterized specificity (30 negatives and 37 positives were used as controls)

Patterns of the COVID19 epidemic spread around the world: exponential vs power laws

Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2)

SARS-CoV-2 titers in wastewater are higher than expected from clinically confirmed cases 

Flattening the curve before it flattens us: hospital critical care capacity limits and mortality from novel coronavirus (SARS-CoV2) cases in US counties- 3 and 6 week projections from April 2, 2020 

Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington

Evaluation of the Effectiveness of Surveillance and Containment Measures for the First 100 Patients with COVID-19 in Singapore — January 2–February 29, 2020

Transmission potential of the novel coronavirus (COVID-19) onboard the diamond Princess Cruises Ship, 2020

Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand

Temporal dynamics in viral shedding and transmissibility of COVID-19 

Excess cases of Influenza like illnesses in France synchronous with COVID19 invasion. 

CoViD–19: An Automatic, Semiparametric Estimation Method for the Population Infected in Italy 

Rational evaluation of various epidemic models based on the COVID-19 data of China 

Strongly heterogeneous transmission of COVID–19 in mainland China: local and regional variation 

The serial interval of COVID-19 from publicly reported confirmed cases 

The effect of control strategies that reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China 

Estimating the infection and case fatality ratio for COVID-19 using age-adjusted data from the outbreak on the Diamond Princess cruise ship 

Modeling the Comparative Impact of Individual Quarantine vs. Active Monitoring of Contacts for the Mitigation of COVID-19 

Early epidemiological assessment of the transmission potential and virulence of coronavirus disease 2019 (COVID-19) in Wuhan City: China, January-February, 2020

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

Preliminary estimating the reproduction number of the coronavirus disease (COVID-19) outbreak in Republic of Korea from 31 January to 1 March 2020

Case fatality risk of novel coronavirus diseases 2019 in China

Epidemiology and Transmission of COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts

Modelling the coronavirus disease (COVID-19) outbreak on the Diamond Princess ship using the public surveillance data from January 20 to February 20, 2020

Estimate the incubation period of coronavirus 2019 (COVID-19)

Secondary attack rate and superspreading events for SARS-CoV-2

Genomic variations of COVID-19 suggest multiple outbreak sources of transmission

An interactive web-based dashboard to track COVID-19 in real time

Multivariate Analyses of Codon Usage of SARS-CoV-2 and other betacoronaviruses

SARS-like WIV1-CoV poised for human emergence -A paper from 2016 rising the prospect of a new bat coronavirus entering the human population

Recombination and convergent evolution led to the emergence of 2019 Wuhan coronavirus

Clinical diagnosis of 8274 samples with 2019-novel coronavirus in Wuhan

Time-varying transmission dynamics of Novel Coronavirus Pneumonia in China

China CDC weekly report

Genomics:

Current phylogeny of SARS CoV-2

https://ncbiinsights.ncbi.nlm.nih.gov/2020/01/13/novel-coronavirus/ 

https://www.ncbi.nlm.nih.gov/nuccore/?term=wuhan+coronavirus

List of available 2019-nCOV sequences (NCBI)